CymaBay stock: buy or sell?
September 20th, 2019
Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.
Should I buy CymaBay stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with CymaBay Therapeutics stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is CymaBay stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we gathered 9 ratings published for CBAY stock in the last 30 days. The general sentiment of these ratings is bullish for CBAY stock, with 7 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-11||Piper Jaffray Companies||Overweight||Market Perform|
CymaBay stock analysis
CymaBay Therapeutics appreciated a beatiful 1.08% and closed at $5.63.
Shares of CymaBay closed yesterday at $5.63 and appreciated a beatiful 1.08%. Since June when CBAY stock price broke down the SMA200d line, it slid $-5.46 per share (-49.23%).
Shares of CymaBay slightly fell a rough -2.09% this week. Late August CBAY climbed a super good 6.59% in just one week. By mid August CBAY plunged a horrible -5.24% in just one week.
CymaBay stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since price and 40-weeks moving average lines crossed down by mid June, CBAY fell $-5.88 per share (-51.09%). Stocks below the 40w moving average line are usually not recommended for average traders.
CymaBay stock price history
CymaBay stock went public on February 3rd, 2014 with a price of $5.001. Since then, CBAY stock grew a 12.60%, with an average of 2.50% per year. If you had invested $1,000 in CymaBay stock in 2014, it would worth $126.00 today.
1: Adjusted price after possible price splits or reverse-splits.
CymaBay stock historical price chart
CBAY stock reached 52-week highs on March at $14.00, and all-time highs 2018-03-05 with a price of 15.59.
CymaBay stock price target is $14.10Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' CBAY stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 8 price predictions for CymaBay stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-17||B. Riley||Set Price Target||n/a||$7.00||-|
|2019-6-11||Piper Jaffray Companies||Lowers Target||$30.00||$8.00||-73.3%|
|2019-4-23||Raymond James||Set Price Target||n/a||$18.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, CymaBay Therapeutics didn't meet the expectations of the experts and posted a fateful EPS of $-0.32 per share when experts were expecting $-0.36.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual revenues report draw of to $10.00 M dollars. When comparing 2017 vs , , profit margin (that is, the net income divided by revenues) a to -275.57%.
|2017||$10 M||-||$-27.56 M-275.6%||-|
Quarterly financial resultsReported quarter earnings marked $-19.45 million with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, CymaBay Therapeutics sales marked a spooky decrease and plummed a -100.00%. Looking back to recent quarterly results, CymaBay Therapeutics posted 4 negative quarters in a row.
|2017-Q1||$4.79 M||-||$-5.35 M-111.7%||-|
|2017-Q4||$5.21 M||8.71%||$-5.04 M-96.9%||-5.74%|
CymaBay ownershipWhen you are planning to invest in a stock, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For CymaBay, 0.74% of all outstanding shares are owned by its staff.
Bearish positions for CBAY stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to CymaBay Therapeutics:
|Market cap||$386.8 M||$82.9 B||$202.9 B||$1.8 B||$2.1 B|
|Total shares||68.7 M||1,640.0 M||5,530.0 M||46.4 M||56.6 M|
|Float shares||50.6 M||1,630.0 M||5,490.0 M||54.2 M||56.1 M|
|- Institutional holdings (%)||88.5%||75.0%||76.2%||85.6%||85.8%|
|- Insider holdings (%)||0.7%||0.1%||0.0%||2.7%||13.4%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$5.43 - $5.65|
|Average true range||$0.30|
|50d mov avg||$5.99|
|100d mov avg||$7.98|
|200d mov avg||$9.30|
CymaBay performanceTo better understand CymaBay performance you must becnhmark its gains with other related stocks in same sector or industry. For CymaBay Therapeutics, the benchmark is made against Bristol-Myers Squibb, Pfizer, PTC Therapeutics and Xencor.